1. Banerjee PN, Hauser WA. Incidence and prevalence. Engel P, Pedley T, editors. Epilepsy: A Comprehensive Textbook. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 45–56.
2. Sharma S, Prasad AN. Genetic testing of epileptic encephalopathies of infancy: an approach. Can J Neurol Sci. 2013;40:10–6.
3. Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord. 2015;17:117–123.
4. Sillanpää M, Kälviäinen R, Klaukka T, Helenius H, Shinnar S. Temporal changes in the incidence of epilepsy in Finland: nationwide study. Epilepsy Res. 2006;71:206–15.
5. Saarinen MM, Sillanpää M, Schmidt D, Virta LJ. Long-term changes in the incidence of childhood epilepsy. A population study from Finland. Epilepsy Behav. 2016;58:81–5.
6. Cowan LD. The epidemiology of the epilepsies in children. Ment Retard Dev Disabil Res Rev. 2002;8:171–81.
8. Mann JR, McDermott S. Maternal pre-eclampsia is associated with childhood epilepsy in South Carolina children insured by Medicaid. Epilepsy Behav. 2011;20:506–11.
9. Syvertsen M, Nakken KO, Edland A, Hansen G, Hellum MK, Koht J. Prevalence and etiology of epilepsy in a Norwegian county-a population based study. Epilepsia. 2015;56:699–706.
10. Ream MA, Mikati MA. Clinical utility of genetic testing in pediatric drug-resistant epilepsy: a pilot study. Epilepsy Behav. 2014;37:241–8.
11. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia. 2010;51:676–85.
12. Zavadenko NN. Neurodevelopmental disorders in children with epilepsy: intellectual disability and autism spectrum disorders. Ep and Par Cond. 2017;9:64–71.
13. Symonds JD, Zuberi SM, Johnson MR. Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatment. Curr Opin Neurol. 2017;30:193–9.
14. Orsini A, Zara F, Striano P. Recent advances in epilepsy genetics. Neurosci Lett. 2018;667:4–9.
15. Mercimek-Mahmutoglu S, Patel J, Cordeiro D, et al. Diagnostic yield of genetic testing in epileptic encephalopathy in childhood. Epilepsia. 2015;56:707–16.
16. Freed D, Aldana R, Weber JA, Edwards JS. The Sentieon Genomics Tools-a fast and accurate solution to variant calling from next-generation sequence data [Internet]. BioRxiv. 2017;[cited 2017 May 12]. Available at : https://doi.org/10.1101/115717
19. Zerbino DR, Achuthan P, Akanni W, et al. Ensembl 2018. Nucleic Acids Res. 2018;46:D1. D754–61.
21. Landrum MJ, Lee JM, Benson M, et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2016;44:D1. D862–8.
22. McKusick VA. Mendelian inheritance in man: a catalog of human genes and genetic disorders. Baltimore: Johns Hopkins University Press; 1998.
23. Welter D, MacArthur J, Morales J, et al. The NHGRI GWAS catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014;42:Database issue. D1001–6.
27. Exome Variant Server NHLBI Exome Sequencing Project (ESP) [Internet]. Seattle: University of Washington; [cited 2021 Jan 12]. Available at : http://evs.gs.washington.edu/EVS/
28. Nagasaki M, Yasuda J, Katsuoka F, et al. Rare variant discovery by deep whole-genome sequencing of 1,070 Japanese individuals. Nat Commun. 2015;6:8018
31. Pal DK, Pong AW, Chung WK. Genetic evaluation and counseling for epilepsy. Nat Rev Neurol. 2010;6:445–53.
33. Trump N, McTague A, Brittain H, et al. Improving diagnosis and broadening the phenotypes in early-onset seizure and severe developmental delay disorders through gene panel analysis. J Med Genet. 2016;53:310–7.
34. Lemke JR, Riesch E, Scheurenbrand T, et al. Targeted next generation sequencing as a diagnostic tool in epileptic disorders. Epilepsia. 2012;53:1387–98.
36. Kodera H, Kato M, Nord AS, et al. Targeted capture and sequencing for detection of mutations causing early onset epileptic encephalopathy. Epilepsia. 2013;54:1262–9.
37. Wang J, Gotway G, Pascual JM, Park JY. Diagnostic yield of clinical next-generation sequencing panels for epilepsy. JAMA Neurol. 2014;71:650–1.
38. Della Mina E, Ciccone R, Brustia F, et al. Improving molecular diagnosis in epilepsy by a dedicated high-throughput sequencing platform. Eur J Hum Genet. 2015;23:354–62.
41. EuroEPINOMICS-RES Consortium; Epilepsy Phenome/Genome Project; Epi4K Consortium. De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. Am J Hum Genet. 2014;95:360–70.
43. Gokben S, Onay H, Yilmaz S, et al. Targeted next generation sequencing: the diagnostic value in early-onset epileptic encephalopathy. Acta Neurol Belg. 2017;117:131–8.
45. Rapaccini V, Esposito S, Strinati F, et al. A Child with a c.6923_6928dup (p.Arg2308_Met2309dup) SPTAN1 mutation associated with a severe early infantile epileptic encephalopathy. Int J Mol Sci. 2018;19:1976
46. Takai A, Yamaguchi M, Yoshida H, Chiyonobu T. Investigating developmental and epileptic encephalopathy using drosophila melanogaster. Int J Mol Sci. 2020;21:6442
47. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on classification and terminology of the international league against epilepsy. Epilepsia. 1989;30:389–99.
48. Avanzini G, Noebels J. Genetics of epilepsy and genetic epilepsies. Montrouge: John Libbey Eurotext; 2009.
49. Minassian BA. The progressive myoclonus epilepsies. Prog Brain Res. 2014;213:113–22.
50. Zhang J, Yang Y, Niu X, et al. Clinical phenotype features and genetic etiologies of 38 children with progressive myoclonic epilepsy. Acta Epileptologica. 2020;2:14
51. Finsterer J. Leigh and Leigh-like syndrome in children and adults. Pediatr Neurol. 2008;39:223–35.
53. Lee HN, Eom S, Kim SH, et al. Epilepsy characteristics and clinical outcome in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). Pediatr Neurol. 2016;64:59–65.
54. Gumus E. Extending the phenotype of Xia-Gibbs syndrome in a two-year-old patient with craniosynostosis with a novel de novo AHDC1 missense mutation. Eur J Med Genet. 2020;63:103637
55. Tucci A, Kara E, Schossig A, et al. Kohlschütter-Tönz syndrome: mutations in ROGDI and evidence of genetic heterogeneity. Hum Mutat. 2013;34:296–300.
57. Poirier K, Hubert L, Viot G, et al. CSNK2B splice site mutations in patients cause intellectual disability with or without myoclonic epilepsy. Hum Mutat. 2017;38:932–41.
58. Selvam P, Jain A, Cheema A, Atwal H, Forghani I, Atwal PS. Poirier-Bienvenu neurodevelopmental syndrome: a report of a patient with a pathogenic variant in CSNK2B with abnormal linear growth. Am J Med Genet A. 2021;185:539–43.
59. Rosenfeld JA, Leppig K, Ballif BC, et al. Genotype-phenotype analysis of TCF4 mutations causing Pitt-Hopkins syndrome shows increased seizure activity with missense mutations. Genet Med. 2009;11:797–805.
60. Clark AJ, Rosenberg EH, Almeida LS, et al. X-linked creatine transporter (SLC6A8) mutations in about 1% of males with mental retardation of unknown etiology. Hum Genet. 2006;119:604–10.
61. Helbig I, Ellis CA. Personalized medicine in genetic epilepsies - possibilities, challenges, and new frontiers. Neuropharmacology. 2020;172:107970
62. Boerma RS, Braun KP, van den Broek MP, et al. Remarkable phenytoin sensitivity in 4 children with SCN8A-related epilepsy: a molecular neuropharmacological approach. Neurotherapeutics. 2016;13:192–7.
63. Lynch JM, Tate SK, Kinirons P, et al. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. Epilepsy Res. 2009;83:44–51.
65. Noachtar S, Rémi J. The role of EEG in epilepsy: a critical review. Epilepsy Behav. 2009;15:22–33.